Loading...

We've got a brand new version of Simply Wall St! Try it out

PharmaEssentia

GTSM:6446
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6446
GTSM
NT$24B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

PharmaEssentia Corporation develops therapeutic products for the treatment of human diseases. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
6446 Share Price and Events
7 Day Returns
-3.6%
GTSM:6446
-2.3%
TW Biotechs
-0.5%
TW Market
1 Year Returns
-37.6%
GTSM:6446
-10.2%
TW Biotechs
17.7%
TW Market
6446 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PharmaEssentia (6446) -3.6% -5.7% -9.6% -37.6% -43% -19.4%
TW Biotechs -2.3% -3.6% -6.6% -10.2% -42.4% -41.3%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 6446 underperformed the Biotechs industry which returned -10.2% over the past year.
  • 6446 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
6446
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for PharmaEssentia's competitors could be found in our database.

6446 Value

 Is PharmaEssentia undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for PharmaEssentia. This is due to cash flow or dividend data being unavailable. The share price is NT$108.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PharmaEssentia's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PharmaEssentia's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6446 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$-5.09
GTSM:6446 Share Price ** GTSM (2019-11-18) in TWD NT$108
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 33.36x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PharmaEssentia.

GTSM:6446 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6446 Share Price ÷ EPS (both in TWD)

= 108 ÷ -5.09

-21.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PharmaEssentia is loss making, we can't compare its value to the TW Biotechs industry average.
  • PharmaEssentia is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does PharmaEssentia's expected growth come at a high price?
Raw Data
GTSM:6446 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -21.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
57.7%per year
Asia Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.65x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PharmaEssentia, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PharmaEssentia's assets?
Raw Data
GTSM:6446 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$8.37
GTSM:6446 Share Price * GTSM (2019-11-18) in TWD NT$108
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.22x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:6446 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6446 Share Price ÷ Book Value per Share (both in TWD)

= 108 ÷ 8.37

12.9x

* Primary Listing of PharmaEssentia.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PharmaEssentia is overvalued based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess PharmaEssentia's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. PharmaEssentia has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6446 Future Performance

 How is PharmaEssentia expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
57.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PharmaEssentia expected to grow at an attractive rate?
  • PharmaEssentia's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • PharmaEssentia's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • PharmaEssentia's revenue growth is expected to exceed the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:6446 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:6446 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 57.7%
GTSM:6446 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 76.9%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 66%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 61.4%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6446 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6446 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 2,700 787 1
2021-12-31 1,921 -1,474 -307 2
2020-12-31 432 -1,053 -1,212 2
2019-12-31 219 -942 -994 2
2019-11-18
GTSM:6446 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 130 -836 -1,113
2019-06-30 129 -919 -1,080
2019-03-31 61 -899 -1,086
2018-12-31 26 -827 -1,040
2018-09-30 4 -823 -930
2018-06-30 4 -749 -882
2018-03-31 4 -755 -878
2017-12-31 4 -790 -872
2017-09-30 4 -750 -862
2017-06-30 5 -762 -898
2017-03-31 6 -696 -904
2016-12-31 5 -657 -845

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PharmaEssentia's earnings are expected to grow significantly at over 20% yearly.
  • PharmaEssentia's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6446 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from PharmaEssentia Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6446 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 3.23 3.23 3.23 1.00
2021-12-31 -1.25 -0.74 -1.76 2.00
2020-12-31 -4.96 -3.62 -6.30 2.00
2019-12-31 -4.54 -4.39 -4.68 2.00
2019-11-18
GTSM:6446 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 -5.09
2019-06-30 -4.93
2019-03-31 -4.97
2018-12-31 -4.76
2018-09-30 -4.26
2018-06-30 -4.04
2018-03-31 -4.03
2017-12-31 -4.01
2017-09-30 -3.96
2017-06-30 -4.15
2017-03-31 -4.29
2016-12-31 -4.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PharmaEssentia will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess PharmaEssentia's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PharmaEssentia has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6446 Past Performance

  How has PharmaEssentia performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PharmaEssentia's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PharmaEssentia does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare PharmaEssentia's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PharmaEssentia's 1-year growth to the TW Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
PharmaEssentia's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PharmaEssentia Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6446 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 130.36 -1,113.15 423.43 797.08
2019-06-30 129.21 -1,079.74 328.24 861.98
2019-03-31 61.13 -1,086.43 287.24 846.90
2018-12-31 26.24 -1,039.76 267.02 785.71
2018-09-30 3.76 -930.34 258.12 695.18
2018-06-30 3.70 -881.70 238.99 666.65
2018-03-31 4.08 -878.02 240.44 660.08
2017-12-31 4.04 -872.31 210.45 683.32
2017-09-30 4.18 -861.80 188.70 691.51
2017-06-30 4.77 -897.94 198.92 712.23
2017-03-31 5.53 -903.88 178.32 737.17
2016-12-31 5.47 -844.92 167.18 685.84
2016-09-30 7.27 -891.95 160.91 719.69
2016-06-30 8.94 -865.20 141.97 709.18
2016-03-31 10.99 -869.88 125.58 727.77
2015-12-31 11.59 -853.20 117.77 713.62
2015-09-30 9.03 -818.51 112.74 700.72
2015-06-30 8.57 -804.28 104.85 697.67
2015-03-31 9.39 -796.18 101.85 699.50
2014-12-31 13.36 -853.11 105.56 765.28
2014-09-30 16.76 -812.16 126.58 707.01
2014-06-30 18.69 -832.91 149.43 707.43
2014-03-31 45.51 -713.03 144.05 618.54
2013-12-31 72.33 -593.15 138.67 529.64
2013-09-30 80.89 -449.01 98.60 426.80
2013-06-30 89.46 -304.87 58.52 323.97
2013-03-31 58.97 -280.46 47.39 279.04
2012-12-31 28.47 -256.06 36.26 234.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PharmaEssentia has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if PharmaEssentia has efficiently used its assets last year compared to the TW Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PharmaEssentia improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess PharmaEssentia's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PharmaEssentia has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6446 Health

 How is PharmaEssentia's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PharmaEssentia's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PharmaEssentia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PharmaEssentia's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PharmaEssentia's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 18.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PharmaEssentia Company Filings, last reported 1 month ago.

GTSM:6446 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1,829.97 89.75 1,373.07
2019-06-30 2,069.29 97.00 1,540.06
2019-03-31 2,230.46 98.45 1,855.95
2018-12-31 2,471.96 99.90 2,166.88
2018-09-30 2,819.95 91.35 2,409.25
2018-06-30 3,036.28 92.80 2,707.07
2018-03-31 3,248.77 94.25 2,953.58
2017-12-31 3,457.49 105.70 3,185.93
2017-09-30 3,696.28 107.15 3,419.25
2017-06-30 3,882.43 98.60 3,567.12
2017-03-31 4,096.06 110.05 3,805.52
2016-12-31 4,270.39 111.50 4,044.34
2016-09-30 4,479.07 112.95 4,217.57
2016-06-30 1,266.62 104.40 976.34
2016-03-31 1,283.72 115.85 1,115.70
2015-12-31 689.56 117.30 563.91
2015-09-30 961.53 118.75 757.14
2015-06-30 1,145.80 120.20 873.58
2015-03-31 1,468.57 113.10 1,125.86
2014-12-31 1,468.57 113.10 1,125.86
2014-09-30
2014-06-30 1,816.27 116.00 1,486.13
2014-03-31 1,816.27 116.00 1,486.13
2013-12-31 2,129.61 0.00 1,783.19
2013-09-30 2,129.61 0.00 1,783.19
2013-06-30 778.60 0.00 403.93
2013-03-31 778.60 0.00 403.93
2012-12-31 549.52 80.86 340.69
  • PharmaEssentia's level of debt (4.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (7% vs 4.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PharmaEssentia has sufficient cash runway for 1.4 years based on current free cash flow.
  • PharmaEssentia has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 15.6% each year.
X
Financial health checks
We assess PharmaEssentia's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PharmaEssentia has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6446 Dividends

 What is PharmaEssentia's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PharmaEssentia dividends. Estimated to be 0% next year.
If you bought NT$2,000 of PharmaEssentia shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PharmaEssentia's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PharmaEssentia's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6446 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.9%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6446 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PharmaEssentia has not reported any payouts.
  • Unable to verify if PharmaEssentia's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PharmaEssentia's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PharmaEssentia has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of PharmaEssentia's dividends in 3 years as they are not expected to pay a notable one for Taiwan, Province of China.
X
Income/ dividend checks
We assess PharmaEssentia's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PharmaEssentia afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PharmaEssentia has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6446 Management

 What is the CEO of PharmaEssentia's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ko-Chung Lin
CEO Bio

Mr. Ko-Chung Lin, Ph.D., is the Founder of PharmaEssentia Corporation and has been its Chief Executive Officer since November 01, 2017. Mr. Lin served as Managing Director of Global Strategy & Development at PharmaEssentia Corporation until November 01, 2017. Mr. Lin served as Chief Executive Officer of PharmaEssentia Corporation since October 6, 2015. Mr. Lin has more than 20 years of successful experience in drug discovery and development. He worked at Monsanto-Searle (US) on HIV protease inhibitor project resulting in an AIDS drug on the market; and at Biogen (US), where Lin led the team to discover their first drug candidate that was later licensed to Merck Co. He is an Inventor of more than 40 patents. Mr. Lin received his PhD from the University of Missouri and postdoctoral research at University of Michigan.

CEO Compensation
  • Insufficient data for Ko-Chung to compare compensation growth.
  • Insufficient data for Ko-Chung to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure of the PharmaEssentia management team in years:

1.3
Average Tenure
  • The average tenure for the PharmaEssentia management team is less than 2 years, this suggests a new team.
Management Team

Ko-Chung Lin

TITLE
Founder & CEO

Snow Chang

TITLE
Senior Manager of Finance
TENURE
1.3 yrs

Jack Hwang

TITLE
GM & Director

Albert Qin

TITLE
Chief Medical Officer
TENURE
1.3 yrs

Narihisa Miyachi

TITLE
Head of Japan Medical Affairs
TENURE
1.3 yrs

YenTung Luan

TITLE
GM & Head of Bioprocess Development Department
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure of the PharmaEssentia board of directors in years:

1.3
Average Tenure
  • The average tenure for the PharmaEssentia board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ching-Leou Teng

TITLE
Chairperson

Jack Hwang

TITLE
GM & Director
TENURE
1.7 yrs

Chao-Ho Chen

TITLE
Director

Tian Chang

TITLE
Director

Patrick Yang

TITLE
Independent Director
AGE
71

Jin-De Chang

TITLE
Independent Director

Lung-Chih Yu

TITLE
Director
TENURE
2 yrs

Kuo-Rong Cheng

TITLE
Director
TENURE
1.3 yrs

Shi-Ying Hsu

TITLE
Director
TENURE
1.3 yrs

Ben-Yuan Chen

TITLE
Director
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess PharmaEssentia's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PharmaEssentia has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6446 News

Simply Wall St News

6446 Company Info

Description

PharmaEssentia Corporation develops therapeutic products for the treatment of human diseases. Its flagship product is ropeginterferon alfa-2b that is used for the treatment of severe flu-like symptoms and neuropsychiatric side effects. The company’s ropeginterferon alfa-2b has orphan drug designation in the United States and the European Union; and plans to commercialize ropeginterferon alfa-2b in North and South America, as well as Asia. It also focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. The company has collaboration agreements with AOP Orphan, Academia Sinica, and Athenex. PharmaEssentia Corporation was founded in 2003 and is headquartered in Taipei, Taiwan.

Details
Name: PharmaEssentia Corporation
6446
Exchange: GTSM
Founded: 2003
NT$23,681,873,124
219,276,603
Website: http://www.pharmaessentia.com
Address: PharmaEssentia Corporation
No. 3, park Street,
13th Floor,
Taipei,
115,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6446 Common Shares Taipei Exchange TW TWD 11. Mar 2014
Number of employees
Current staff
Staff numbers
0
PharmaEssentia employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 15:16
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/10/25
Last earnings filing: 2019/11/13
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.